Pfizer Inc. (PFE), Novartis AG (ADR) (NVS): Will a Band-Aid Be Enough for Johnson & Johnson (JNJ)’s Latest Recall?
Johnson & Johnson (NYSE:JNJ) recently announced a recall of around 200,000 bottles of Motrin Infants' Drops Original Berry Flavor.
Posts Tagged ‘Pfizer Inc (PFE)’
GlaxoSmithKline plc (ADR) (GSK), Pfizer Inc. (PFE): Theravance Inc (THRX) Gets Big Win for New COPD Drug
Trading of biopharmaceutical company Theravance Inc (NASDAQ:THRX) was halted on Tuesday. A major decision hung in the balance as the U.S.
Pfizer Inc. (PFE), Regeneron Pharmaceuticals Inc (REGN), Amgen, Inc. (AMGN): Invest in the Next Biotech Frontier
The last several months have been remarkably exciting in the biotech space.
Pfizer Inc. (PFE): Is Seattle Genetics (SGEN) an Acquisition Target?
In late August, Amgen agreed to buy Onyx Pharmaceuticals in one of the worst-kept M&A secrets of the year.
Incyte Corporation (INCY), Pfizer Inc. (PFE): This Biotech Has So Many Reasons to Be Liked
Earlier this month, I wrote an article explaining that I liked Incyte Corporation (NASDAQ:INCY) on the basis of the blockbuster potential of its only approved drug, Jakafi...
Johnson & Johnson (JNJ), Forest Laboratories, Inc. (FRX), Pfizer Inc. (PFE): Pharmas Spending the Most to Catch Your Doctor’s Eye
Pharmaceutical firms spend a lot of money to influence physicians to prescribe their products.
Pfizer Inc. (PFE), Merck & Co., Inc. (MRK): Two Reasons This Biotech Hardly Moved After a Successful Trial
Adding Esperion Therapeutics' ECT-1002 to Pfizer Inc. (NYSE:PFE)'s Lipitor lowered bad LDL cholesterol levels by 22%.
Pfizer Inc. (PFE): Arena Pharmaceuticals, Inc. (ARNA) Pushes Forward
As much as I think Arena Pharmaceuticals, Inc.
Pfizer Inc. (PFE), Arena Pharmaceuticals, Inc. (ARNA), VIVUS, Inc. (VVUS): Two Lucrative Drug Markets You Should Avoid
You really don't need both. There are enough people with rheumatoid arthritis or high cholesterol, for example, to have multiple blockbuster drugs that treat the diseases.
Johnson & Johnson (JNJ), Pfizer Inc. (PFE), Novartis AG (ADR) (NVS): The Biggest Winners of the FDA’s Breakthrough Designation
Designed as a way to bring potentially life-changing drugs to pharmacy shelves faster than ever, the Food and Drug Administration Safety and Innovation Act, which passed last ...
Lexicon Pharmaceuticals, Inc. (LXRX), Pfizer Inc. (PFE), GlaxoSmithKline plc (ADR) (GSK): Why Clinical Trials Fail
Drugs fail their clinical trials for all kinds of reasons. Sometimes, it's related to efficacy; sometimes, it's safety related.
Pfizer Inc. (PFE), Zoetis Inc (ZTS), Merck & Co., Inc. (MRK), Sanofi SA (ADR) (SNY): 5 Reasons to Invest in Animal Health
In an attempt to further simplify its business and unlock shareholder value, Pfizer Inc. (NYSE:PFE) has been busy divesting itself of non-core assets.
Hedge Funds Are Buying Novartis AG (ADR) (NVS)
In the 21st century investor’s toolkit, there are dozens of methods market participants can use to monitor the equity markets.
Pfizer Inc. (PFE): The Procter & Gamble Company (PG)’s Fall Can’t Stop the Dow Jones Industrial Average (.DJI)’s Bounce
Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing...
Pfizer Inc. (PFE), GlaxoSmithKline plc (ADR) (GSK): Can This HIV Drug Challenge Gilead Sciences, Inc. (GILD)’s Domination?
ViiV Healthcare -- a joint venture by Pfizer Inc.
Pfizer Inc. (PFE), GlaxoSmithKline plc (ADR) (GSK), Merck & Co., Inc. (MRK): Which Pharmaceutical Giant Faces the Steepest Patent Cliff?
At the same time, the pharmaceutical industry isn't without its share of risks.
Pfizer Inc. (PFE), Gilead Sciences, Inc. (GILD), Merck & Co., Inc. (MRK) Among Hedge Funds’ Favorite Pharma Stocks
We maintain a database of quarterly 13F filings from hundreds of hedge funds and other notable investors.
Amgen, Inc. (AMGN) and Onyx Pharmaceuticals, Inc. (ONXX): Half a Billion Dollars’ Worth of Drama
A finale has at last arrived for the biotech drama of summer 2013. Amgen, Inc. (NASDAQ:AMGN) announced yesterday that it will buy Onyx Pharmaceuticals, Inc.
Pfizer Inc. (PFE), Amgen, Inc. (AMGN), UnitedHealth Group Inc. (UNH): Do Health Care Stocks Fall in the Fall?
Every investor has heard the old line "sell in May and go away." That wasn't such great advice this year with the S&P 500 index up nearly 5% since the beginning of May.
Pfizer Inc. (PFE), United Therapeutics Corporation (UTHR): How Big Is Organovo Holdings Inc (ONVO)’s Market Opportunity?
Organovo Holdings Inc (NYSEMKT:ONVO) is a little company that people think could do big things.
ConocoPhillips (COP), Pfizer Inc. (PFE), Cytec Industries Inc (CYT): Forget Bernanke, Invest Alongside His Potential Successor
At StreetAuthority, we often look at where Washington's most powerful men are putting their money.
Pfizer Inc. (PFE), Eli Lilly & Co. (LLY), Forest Laboratories, Inc. (FRX): The Past, Present, and Future of Alzheimer’s Treatments
Editor’s Note: A previous version of this post incorrectly stated that Eli Lilly’s experimental drug solanezumab is a BACE inhibitor.
Pfizer Inc. (PFE), Novartis AG (ADR) (NVS): Does Incyte Corporation (INCY) Deserve Its New Valuation?
One of the hottest stocks on the market Wednesday was Incyte Corporation (NASDAQ:INCY), a pharmaceutical company specializing in the development of JAK inhibitors.
Pfizer Inc. (PFE), United Therapeutics Corporation (UTHR): Organovo Holdings Inc (ONVO)’s Earnings, Patience Is Necessary
Imagine a day where there are no waiting lists for liver transplants. Instead, patients can have a perfectly tailored liver bioprinted and placed into their body.
Pfizer Inc. (PFE), Regeneron Pharmaceuticals Inc (REGN): Are These Drugs the Future of High-Cholesterol Treatment?
Once upon a time in a regulatory environment far, far away, there was a cholesterol-fighting drug named Lipitor from Pfizer Inc. (NYSE:PFE).
Express Scripts Holding Company (ESRX), Community Health Systems (CYH), Pfizer Inc. (PFE): Why Health-Care Costs Are Likely to Rise
Opinions rage about whether health insurance costs will rise or fall with implementation of the Affordable Care Act, commonly known as Obamacare.
Johnson & Johnson (JNJ), Express Scripts Holding Company (ESRX), Gilead Sciences, Inc. (GILD): Three Great Buy-and-Hold Health-Care Stocks
This could have been an enormously more difficult effort. I started out with the goal to identify the three best stocks in health care to buy and hold for years, even decades.
AT&T Inc. (T), Intel Corporation (INTC), Pfizer Inc. (PFE): An Even Simpler Path to Dow Dividend Riches?
Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing...
Merck & Co., Inc. (MRK), Pfizer Inc. (PFE): Alarming New Obesity Data Points to a Scary Trend
Last week, the Trust for America's Health and the Robert Wood Johnson Foundation released their annual report (link opens a PDF to a 116-page report) on obesity trends in the ...
AT&T Inc. (T), Pfizer Inc. (PFE): Dow Jones Industrial Average (.DJI) Ends the Week With a Whimper as Verizon Communications Inc. (VZ) Drops
Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing...
MannKind Corporation (MNKD), Novo Nordisk A/S (ADR) (NVO), Eli Lilly & Co. (LLY): Dreamboat Data? Not Exactly.
MannKind Corporation (NASDAQ:MNKD) ended up more than 10% on Wednesday, after the biotech announced positive results for two phase 3 trials testing its inhaled insulin Afrezza...
Billionaire Stanley Druckenmiller Traded Homebuilders for Google Inc (GOOG) Last Quarter: Lennar Corporation (LEN), D.R. Horton, Inc. (DHI)
In August, billionaire Stanley Druckenmiller’s family office (Druckenmiller is the former head of Duquesne Capital) filed its 13F for the second quarter of 2013 with the SEC...
MannKind Corporation (MNKD): What’s the Latest: New Insulin Inhaler, Rating Reiterated by Zacks, Matthew J. Pfeffer & More
The long promise of insulin that diabetics can inhale appears to be moving closer to the market.
Organovo Holdings Inc (ONVO), 3D Systems Corporation (DDD): A Tiny 3-D Printing Company I’m Buying
Ever since August 2011, I've been calling out one or two companies every month that I was putting my own retirement money behind.
eBay Inc (EBAY), Pfizer Inc. (PFE): Does a PayPal Spinoff Make Sense?
The ideal situation for a spinoff is when you have a small, fast growing division lodged within a large, slower-growing company.
GlaxoSmithKline plc (ADR) (GSK), Merck & Co., Inc. (MRK): The 10 Most Common Reasons People Visit Their Doctor
With the full implementation of the individual portion of the Patient Protection and Affordable Care Act less than five months away, physicians and doctor's offices around the...
General Electric Company (GE), The Procter & Gamble Company (PG), Microsoft Corporation (MSFT): The Ten Most Popular Stocks Owned By Congress
I don't know which is worse: The fact that insider trading was legal for some of our nation's wealthiest politicians...
MannKind Corporation (MNKD), Novo Nordisk A/S (ADR) (NVO), Eli Lilly & Co. (LLY): A Good Drug That’s Too Risky to Buy
In a companion article a few days ago, I predicted that MannKind Corporation (NASDAQ:MNKD)'s extended phase 3 program for its inhaled insulin, Afrezza, is likely to produce ...
Amgen, Inc. (AMGN), Pfizer Inc. (PFE), Merck & Co., Inc. (MRK): A Closer Look at the Battle Over Cancer Treatments
Over the past year, the battle over cancer treatments has heated up considerably. Big pharma companies such as Amgen, Inc. (NASDAQ:AMGN), Pfizer Inc.
AEterna Zentaris Inc. (USA) (AEZS), Tower Group International, Ltd. (TWGP): Stocks to Get on Your Watchlist
I follow quite a lot of companies, so the usefulness of a watchlist to me cannot be overstated.
Pfizer Inc. (PFE), Merck & Co., Inc. (MRK), Aegerion Pharmaceuticals, Inc. (AEGR): Will This Speculative Cholesterol Treatment Pay Off?
In America, 33.5% of adults over the age of 20 have high LDL (“bad”) cholesterol levels, according to the CDC.
Bristol-Myers Squibb Co (BMY), Johnson & Johnson (JNJ): Buy These Leading Pharma Companies
A recent EvaluatePharma report estimated the market for prescribed drugs will increase at an annual rate of 3.8% to $895 billion from 2012 to 2018.
Teva Pharmaceutical Industries Ltd (ADR) (TEVA), AstraZeneca plc (ADR) (AZN): A Safe Investment With Growth Promise
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has been stuck is share purgatory for a number of years.
Pfizer Inc. (PFE), Amgen, Inc. (AMGN): The Best-Selling Medications of 2013 (So Far)
Believe it or not, 2013 is getting close to being two-thirds of the way over. Many pharmaceutical firms have enjoyed great stock returns and nice profits thus far in the year.
Theravance Inc (THRX), Novartis AG (ADR) (NVS): Respiratory Drug Maker About to Take Off
Chronic obstructive pulmonary disease (COPD) is America’s third leading cause of death.
Pfizer Inc. (PFE), Merck & Co., Inc. (MRK): Will Zoetis Earnings Deliver on Post-Spinoff Growth?
Zoetis will release its quarterly report on Tuesday, and investors will get their first look at the company as a completely independent business entity.
Eli Lilly & Co. (LLY), Novartis AG (ADR) (NVS): Is This Company Getting Ahead of Itself?
The biotechnology industry is one of the riskiest places to put your money. However, when companies get everything right, the fortunes made there are usually massive.
Pfizer Inc. (PFE), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK): Will Healthcare Take Care of Your Portfolio
During the past decade, healthcare has been one of the most stable and consistent performers among all industries.
Pfizer Inc. (PFE), Eli Lilly & Co. (LLY), Bristol-Myers Squibb Co (BMY): These Pharmaceutical Giants Are Teetering Dangerously Near The Patent Cliff
In the hunt for sustainable dividend yields, investors have rushed into the stocks of major pharmaceutical companies.
Incyte Corporation (INCY) Earnings Cruise on Jakafi Growth
Budding biotech company Incyte Corporation (NASDAQ:INCY), which specializes in developing novel JAK inhibitors, released solid second-quarter earnings on Wednesday.
